Reporting remotely on findings presented at ASCO 2020 Virtual Meeting, Egbert Smit comments on important and potentially practice changing study results in NSCLC.
He first discusses reduced risk of progression with 3 years of adjuvant treatment with osimertinib in patients with stage IB–IIIA EGFR mutation positive NSCLC after complete tumour resection that was demonstrated in the ADAURA trial. Although overall survival results are not mature, the results in terms of response duration may be practice changing. Secondly he talks about the results of the DESTINY-Lung01 study evaluating objective response to trastuzumab deruxtecan in patients with HER2-mutated metastatic NSCLC. Finally he looks at positive results from the CheckMate 9La trial testing addition of nivolumab plus ipilimumab to 2 cycles of chemotherapy vs 4 cycles of chemotherapy as first-line treatment for patients with metastatic/recurrent NSCLC.
Abstracts:
- LBA5: Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA - Roy Herbst
- 9504: Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01 - Egbert Smit
- 9501: Nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of platinum-doublet chemotherapy (chemo) vs 4 cycles chemo as first-line (1L) treatment (tx) for stage IV/recurrent non-small cell lung cancer (NSCLC): CheckMate 9LA - Martin Reck